In the present study our group showed the utility of intravesical instillation of the ICG pHLIP® (ICG is a FDA approved near infrared fluorescent dye and pHLIP® is a pH (Low) Insertion Peptide, which targets tumor acidity) construct for bladder tumor identification and staging. The molecule was also able to identify dysplastic tissue which may represent a premalignant lesion. If premalignant lesions could be identified in a reliable and actionable fashion this might offer the opportunity of preventing disease progression and subsequent patient morbidity. Furthermore, in an era of rising healthcare costs for both patients and institutions, early detection and prevention may represent significant savings in treatment and follow up surveillance costs.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
As a pilot study, our publication requires further validation and investigation in a larger population of patients. Further efforts will focus on the prospects for intravenous administration of this or similar constructs for targeted fluorescence, contrast or drug delivery. Current foci for investigation at our institution include IRB approved projects applying the ICG pHLIP® construct to upper tract urothelial and renal cell neoplasms for tumor identification and staging purposes. Preliminary results are encouraging as we optimize specimen preparation regimens.
With the dubious honor of having the highest per capita incidence of bladder cancer in the nation, Rhode Island represents a unique patient population. We thank the patients who participated in this study and those who will assist in studies to come. With the application of this and other burgeoning technologies, we hope to improve the quality of care delivered to bladder cancer patients both locally and abroad.
Written by: Joseph M Brito, Yana K Reshetnyak, and Dragan Golijanin
1. Demoin et al. PET Imaging of Extracellular pH in Tumors with (64)Cu- and (18)F-Labeled pHLIP Peptides: A Structure-Activity Optimization Study Bioconjug Chem. 2016, 27(9), 2014-2023.